Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNA C - EuroVacc

Drug Profile

DNA C - EuroVacc

Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVacc

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EuroVacc Foundation; GENEART; University of Regensburg
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 28 Dec 2020 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
  • 08 Mar 2020 Efficacy and safety data from a phase I/IIa trial in HIV uninfected volunteers presented at the 27th Conference on Retroviruses and Opportunistic Infections (CROI-2020)
  • 28 Jan 2020 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in South Africa (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top